Background and Purpose: Expression of the pro-fibrotic galectin-3 and the proapoptotic BIM is elevated in diseased heart or after β-adrenoceptor stimulation, but the underlying mechanisms are unclear. This question was addressed in the present study.
induced YAP phosphorylation and expression of galectin-3 and BIM, effects simulated by forskolin but abolished by PKA inhibitors, and YAP knockdown induced expression of galectin-3 and BIM.
Conclusions and Implications: Stimulation of cardiac β-adrenoceptors activated the Mst1/Hippo pathway leading to YAP hyper-phosphorylation with enhanced expression of galectin-3 and BIM. This signalling pathway would have therapeutic potential.
LINKED ARTICLES:
This article is part of a themed section on AdrenoceptorsNew Roles for Old Players. To view the other articles in this section visit http:// onlinelibrary.wiley.com/doi/10.1111/bph.v176.14/issuetoc 1 | INTRODUCTION Activation of the sympatho-β-adrenergic system is a hallmark of heart disease and heart failure (Kaye et al., 1995; Triposkiadis et al., 2009 ).
Stimulation of β-adrenoceptors leads to inotropic and lusitropic actions to maintain cardiac performance (Kaumann et al., 1999) . However, in the setting of heart disease, sustained stimulation of β-adrenoceptors, due to enhanced sympathetic nervous activation with elevated catecholamine levels is associated with adverse prognosis (Cohn et al., 1984; Kaye et al., 1995) . It is well known that sustained β-adrenoceptor stimulation leads to adverse cardiac effects notably fibrosis and cardiomyocyte apoptosis (Triposkiadis et al., 2009; Xiao et al., 2018) . Understanding the mechanisms that drive myocardial fibrosis and apoptosis is essential for the development of new therapies.
Galectin-3 (Gal-3) is a β-galactoside-specific lectin that binds to intracellular and extracellular glycoproteins regulating their function particularly under diseased conditions (Meijers, Lopez-Andres, & de Boer, 2016; Nguyen et al., 2018; Takemoto et al., 2016) . Clinically, Gal-3 is regarded as a biomarker predicting the risk of heart failure, atrial fibrillation, or all-cause mortality (Filipe, Meijers, Rogier van der Velde, & de Boer, 2015; Ghorbani et al., 2018) . Meanwhile, Gal-3 is implicated as a causative mediator of cardiac inflammation and fibrosis Rabinovich & Toscano, 2009; Suthahar et al., 2018; Takemoto et al., 2016; L. Yu et al., 2013) . In the context of apoptosis, the Bcl-2 interacting mediator of cell death (BIM) is a BH3-only protein of the Bcl-2 family and an essential initiator of apoptosis in diverse physiological and diseased settings (Bouillet & O'Reilly, 2009; Puthalakath et al., 2007) . BIM senses pro-apoptotic signals and activates pro-apoptotic BAX and BAK while inhibiting anti-apoptotic proteins such as Bcl-2 and Mcl-2 (Bouillet & O'Reilly, 2009 ). We previously showed that cardiac expression of BIM is elevated by treatment with isoprenaline or myocardial ischaemia (Y. Y. Lee et al., 2013) .
Isoprenaline-induced apoptosis is abolished in hearts or cultured cardiomyocytes of BIM knockout (KO) mice (Y. Y. Lee et al., 2013) .
Collectively, there is good evidence for Gal-3 and BIM as potential therapeutic targets to inhibit cardiac fibrosis and apoptosis. However, the mechanism responsible for the up-regulated expression of both molecules in heart disease is unknown.
We recently observed in transgenic (TG) mice with cardiac overexpression of mammalian sterile-20 like kinase 1 (Mst1) that expression of Gal-3 was elevated by approximately 50-fold (Nguyen et al., 2018) .
Being the mammalian ortholog of Drosophila Hippo kinase, Mst1 is the key kinase of the Hippo signalling pathway that is known to control organ size through regulation of cell proliferation and survival (F. X. Yu, Zhao, & Guan, 2015) . Recent studies indicate a role of the Hippo pathway in diseased conditions such as tumour growth, heart disease, and regenerative medicine (Ikeda & Sadoshima, 2016; Leach et al., 2017;  F. X. Yu et al., 2015) . Studies have also reported coupling of GPCRs, including β-adrenoceptors, to the Hippo pathway (Kimura et al., 2016;  F. X. Yu et al., 2012) , although the downstream target genes that contribute to myocardial fibrosis and apoptosis remain unknown.
In the current study, our central hypothesis was that cardiac β-adrenoceptor stimulation up-regulated expression of Gal-3 and BIM through the Hippo signalling pathway. We have examined β-adrenoceptor-mediated activation of cardiac Mst1/Hippo pathway,
What is already known
• Stimulation of cardiac β-adrenoceptors induces expression of Gal-3 and BIM as pro-fibrotic and proapoptotic molecules.
What this study adds
• The β-adrenoceptor-Mst1(Hippo)-YAP signalling pathway mediated the up-regulated expression of Gal-3 and BIM in the heart.
What is the clinical significance
• Therapy with β-adrenoceptor antagonists in heart disease could inhibit this adverse β-adrenoceptor-Hippo signalling.
• The β-adrenoceptor-Mst1(Hippo) pathway provides a therapeutic target to down-regulate Gal-3 and BIM in heart disease.
in relation to expression of Gal-3 and BIM and explored the role of YAP as the key transcription co-regulator. Our findings establish β-adrenoceptor-Mst1(Hippo)-YAP signalling as a controlling factor in the expression of Gal-3 and BIM in cardiac tissues.
| METHODS

| Animals
All animal care and experimental procedures in this study were approved by the local animal ethics committee in compliance with the Australian Code for the Care and Use of Animals for Scientific Purposes (8th edition) and animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010 , McGrath & Lilley, 2015 . Male C57BL/6J mice (12-16 weeks of age, RRID:IMSR_JAX:000664; from breeding stock at AMREP Animal Centre, Melbourne, Australia) were used. We used three TG strains of mice with transgenes driven by the α-myosin heavy chain promoter to achieve cardiomyocyte-specific expression of human β 2 -adrenoceptors (β 2 -TG; Milano et al., 1994) , Mst1 (Mst1-TG), or dominant-negative mutant Mst1 (dnMst1-TG; Yamamoto et al., 2003) . All strains of mice were on a C57BL/6J genetic background. Only maleTG and non-transgenic (nTG) mice were studied.
Age-matched non-TG littermates (nTG) were used as controls. Mice were housed in standard conditions with food and water provided ad libitum. Gal-3 gene deleted strain of mice (Gal-3 KO in C57BL/6J background) was obtained from Jackson Laboratories (Bar Harbor, ME).
Mice were assigned randomly to different experimental groups.
In the β 2 -TG strain, cardiac β 2 -adrenoceptor density increases by approximately 200-fold (equivalent to 30-fold increase in density of total β-adrenoceptors; Milano et al., 1994; Xu et al., 2011) . The β 2 -TG mice exhibit age-dependent development of cardiac fibrosis, cardiomyocyte loss, hypertrophy, ventricular arrhythmias, and heart failure (Du et al., 2000; Nguyen et al., 2015; Xu et al., 2011) . With a 7.5-fold increase in Mst1 activity, Mst1-TG mice show early onset of dilated cardiomyopathy and severe interstitial fibrosis and are prone to atrial fibrillation Pretorius et al., 2009; Yamamoto et al., 2003) . Cardiomyocyte expression of kinasedead mutant Mst1 (K59R) transgene acts as a dominant-negative inactivating endogenous Mst1 activity (Yamamoto et al., 2003) . Both dnMst1-TG and Gal-3 KO strains of mice exhibit no cardiac phenotype under basal conditions. In all mouse strains used, body weight was comparable to respective wild-type littermates.
| Echocardiography and organ weights
Echocardiography was performed using an iE33 ultrasound system (Andover, MA) with images analysed in a blinded fashion (Donner, Kiriazis, Du, Marwick, & McMullen, 2018) . Minipumps were removed to allow for washout of isoprenaline overnight, prior to imaging. Under isoflurane anaesthesia, a short-axis view of the left ventricle (LV) and 2D-guided M-mode traces were obtained. LV dimensions at diastole and systole were measured, and fractional shortening (FS) was calculated. At the end, animals were killed by anaesthetic overdose (mixture of ketamine/xylazine/atropine at 200/40/2.4 mg·kg −1 , respectively, i.p.). Weights of the heart, LV, and lungs were obtained, and tibia length was determined.
| Hydroxyproline assay for collagen
Myocardial fibrosis was determined by hydroxyproline assay as previously described (Nguyen et al., 2015) . An apical portion of the LV (about 20 mg) was used for the assay with hydroxyproline values converted into total collagen content. Results were normalized by dry weight of LV tissue. Louis, MO). Cytoplasmic and nuclear fractions of protein were prepared as we previously described (Gao et al., 2011) . Tissues were minced in homogenization buffer containing protease and phosphatase inhibitor cocktails and lysed by homogenization. Homogenates were centrifuged (5,000× g, 10 min at 4°C). The supernatants containing cytoplasmic proteins were collected. Pellets were carefully resuspended in a nuclear extraction buffer containing protease and phosphatase inhibitor cocktails. Quick freeze-thaw of pellet suspensions in liquid nitrogen was done three times, followed by centrifugation (12,000× g, 15 min at 4°C). The resulting supernatants containing nuclear protein were collected. Protein concentration was determined using Pierce BCA protein assay kit (#23227, Thermo Scientific, Rockford, IL).
| Cell experiments
Protein level of Gal-3 in LV tissue was measured using the mouse FastX Toolkit was used to trim low quality bases. Reads were mapped with STAR (Dobin et al., 2013) to the mouse genome downloaded from Ensembl (GRCm38, RRID:SCR_002344). FeatureCount (Liao, Smyth, & Shi, 2014 ) was used to count reads mapped to gene exons on the correct strand with a minimum mapping quality of 20 using Ensembl genome annotation (Mus musculus. GRCm38.85.gtf). Genes with fewer than 10 reads per sample on average were excluded. The resulting count matrix was analysed with the EdgeR package (Robinson, McCarthy, & Smyth, 2010) . Genes were ranked from most up-regulated to most downregulated by multiplying the sign of the log 2 fold change by the inverse of the P value. Enrichment tests were performed using GSEA-P (Subramanian, Kuehn, Gould, Tamayo, & Mesirov, 2007) . YAP target genes were defined as having a peak within 1 kbp of a transcriptional start site according to YAP ChIP-seq data available from Cistrome DB (Lin et al., 2015) .
| Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018) . Data are presented as mean ± SEM, unless otherwise stated.
According to our previous studies and/or preliminary experiments on protein expression for intra-group variation and differences between group means, we calculated the group size and found that n = 5 was sufficient to detect a difference with 95% confidence and 80%
power. All results were analysed using GraphPad Prism 7 Software (RRID:SCR_002798). Shapiro-Wilk's and Levene's tests were used to determine normality and equal variance, respectively. Data were tested by either one-or two-way ANOVA, followed by Bonferroni post hoc test. For datasets of only two groups, a Student's t test was used to compare differences. P < .05 was considered as statistically significant.
| Materials
Isoprenaline and propranolol, carvedilol, atenolol, and ICI-118551
were supplied by Sigma. These compounds were dissolved in saline and BIM were significantly higher in hearts from β 2 -TG mice than in those from nTG mice, at 4 and 8 months of age (Figure 1f,g ). , s.c.) for 1, 2, or 7 days (n = 5 per group), respectively. *P < .05, significantly different from control (CTL), # P < .05, significantly different from isoprenaline (1 day). Cardiac expression of Gal-3 in mice treated with isoprenaline for 2 days at 0.6, 6, or 20 mg·kg −1 ·day −1 (n = 5 per group), respectively. *P < .05, significantly different from CTL, # P < .05, significantly different from isoprenaline (0.6 mg·kg −1 ·day ) or combination of both (n = 6 per group). *P < .05, significantly different from CTL, # P < .05, significantly different from isoprenaline alone. (d) Cardiac expression of BIM in mice treated with isoprenaline (6 mg·kg −1 ·day −1 ) for 1, 2, or 7 days (n = 5 per group), respectively. *P < .05, significantly different from CTL; # P < .05, significantly different from isoprenaline (1 day). Cardiac expression of BIM in mice treated for 2 days with isoprenaline at 0.6, 6, or 20 mg·kg ·day −1 ; n = 5 per group).
*P < .05, significantly different from CTL, # P < .05, significantly different from isoprenaline alone. (f, g) Cardiac expression of Gal-3 (f, n = 9 per group) or BIM (g, n = 5 per group) in nTG and β 2 -TG mice at 4 and 8 months of age. *P < .05, significantly different from age-matched nTG, # P < .05, significantly different from 4-month β 2 -TG. Data shown are means ± SEM. Results were compared by one-way (a-e) or two-way (f-g)
ANOVA followed by Bonferroni post hoc test
| Pharmacological or genetic β-adrenoceptor activation induces Mst1 expression and YAP phosphorylation
We explored the mechanism by which β-adrenoceptor activation up- Mst1 and YAP were also determined in β 2 -TG mouse hearts. Mst1 protein expression was significantly and age-dependently upregulated in β 2 -TG hearts (Figure 3a) . Increased p-YAP was observed in the β 2 -TG hearts (Figure 3b ), indicating YAP inactivation in the setting of heightened β-adrenoceptor activity. In β 2 -TG hearts, total YAP was unchanged at 4 months of age but increased by 20% at 8 months of age, whereas p-YAP, normalized by either total protein or total YAP, was increased at both ages studied (Figure 3b ). , 2 days). *P < .05, significantly different from CTL. All data sets, n = 5 per group. Data shown are means ± SEM and were compared by two-tailed Student's t test (a, e) or one-way ANOVA (a-d), followed by Bonferroni post hoc test 
| Influence of Gal-3 on expression of YAP-target genes
We determined the expression of three YAP-target genes, that is, connective tissue growth factor (CTGF), ankyrin repeat domain 1 (Ankrd1), and baculoviral IAP repeat containing 5 (Birc5), with their expression known to be activated by YAP (Chen et al., 2014; Matsuda et al., 2016; Plouffe et al., 2016) . These selected genes were consistently up-regulated in the heart of isoprenaline-treated mice or Mst1-TG mice (Figure 7a ). The effects of Gal-3 on the expression of these genes was studied. Specifically, expression of these genes was determined in LV tissues from wild-type control or Gal-3 KO mice treated with isoprenaline (30 mg·kg 
| ISO induced cardiotoxicity and effect of Gal-3 gene deletion
Our previous study showed that isoprenaline-induced cardiomyocyte apoptosis is dependent on the induction of BIM (Y. Y. Lee et al., 2013) . Here, we studied the effect of Gal-3 in isoprenaline-induced cardiotoxicity. In wild-type control mice, isoprenaline treatment ). Under Lee et al., 2013) . We showed that isoprenaline-induced cardiac expression of Gal-3 and BIM was significantly inhibited by the concomitant treatment with non-selective β-adrenoceptor antagonists. These findings imply that Gal-3 and BIM as potential therapeutic targets to suppress β-adrenoceptor-mediated cardiac fibrosis and apoptosis. Furthermore, we found that isoprenaline-induced Gal-3 expression was suppressed not only by non-selective β-adrenoceptor antagonists but also by selective β-adrenoceptor antagonists, atenolol and ICI-118551 with only a trend for further inhibition when combined. This might be explained by similar Gsα/cAMP/PKA coupling of β 1 -and β 2 -adrenoceptor mediating similar cellular excitation (Kaumann et al., 1999; Kaumann & Lemoine, 1987) . This is particularly true in the diseased myocardium where β 2 -adrenoceptors are redistributed, thereby mediating a broader signalling than the β 1 -adrenoceptors (Nikolaev et al., 2010; Wright et al., 2014) . In addition, ICI-118551 at 0.1 μM or higher concentrations will block effects mediated by β 1 -adrenoceptors (Kaumann & Lemoine, 1987; O'Donnell & Wanstall, 1980) or chronotropic response to sympathetic nerve stimulation in perfused mouse hearts (Du et al., 1996) .
BIM is an essential initiator of apoptosis (Bouillet & O'Reilly, 2009; Puthalakath et al., 2007) . We previously showed that BIM gene deletion is cardioprotective against isoprenaline-induced cardiotoxicity (Y. Y. Lee et al., 2013) . Specifically, with chronic isoprenaline treatment, BIM KO mice were resistant, relative to wild-type controls, to isoprenaline-induced cardiomyocyte apoptosis, hypertrophy, and ventricular dysfunction. In Gal-3 KO mice, cardiac damage induced by treatment with isoprenaline for 7 days was abolished as shown by the absence of LV dysfunction and fibrosis and blunted fibrotic and inflammatory signalling. Thus, Gal-3 and BIM are critical molecules in mediating cardiotoxicity induced by β-adrenoceptor stimulation. , 2 days; n = 5 per group). *P < .05, significantly different from respective CTL; # P < .05, significantly different from nTG + isoprenaline. (g) Protein levels of p-YAP and YAP in nTG and dnMst1-TG mice treated with isoprenaline (6 mg·kg −1 ·day −1
, 2 days; n = 5 per group). *P < .05, significantly different from respective CTL; # P < .05, significantly different from nTG + isoprenaline. Data shown are means ± SEM and were compared by two-tailed Student's t test (a-c), one-way (e) or two-way (d, f, g) ANOVA, followed by Bonferroni post hoc test FIGURE 5 PKA is involved in β-adrenoceptor-induced YAP phosphorylation as well as Gal-3 and BIM up-regulation in H9c2 cells. H9c2 cells were pretreated with H89 (20 μM) or PKI 14-22 (10 μM) for 30 min prior to addition of isoprenaline (ISO; 3 μM) for 48 hr. Panels a and b are representative immunoblotting images and grouped data of p-YAP and YAP (a) or Gal-3 and BIM (b) in H9c2 cells after isoprenaline treatment alone or combined with H89. Panels c and d are representative immunoblotting images and grouped data of p-YAP and p-YAP/YAP ratio (c) or Gal-3 and BIM (d) in H9c2 cells after isoprenaline treatment alone or combined with PKI. For panels a-d, *P < .05, significantly different from CTL, # P < .05, significantly different from isoprenaline alone. H9c2 cells were treated with the AC activator forskolin (FSK, 10 μM) for 24 hr. Panels e and f show representative immunoblotting images and grouped data of p-YAP and YAP (e) or protein expression levels of Gal-3 and BIM (f). (g) Effect of isoprenaline (3 μM, 48 hr) or forskolin (10 μM, 24 hr) on Mst1 protein expression. For panels e-g, *P < .05, significantly different from CTL. For all data sets, n = 5 per group. Data shown are means ± SEM and were compared by two-tailed Student's t test (e-g) or one-way ANOVA (a-d) followed by Bonferroni post hoc test Similar to isoprenaline treatment, up-regulated expression of Gal-3 and BIM was found in the β 2 -TG mouse heart. Furthermore, we also showed elevated cardiac expression of Mst1 by isoprenaline treatment or in β 2 -TG hearts. These findings guided us to explore the possibility that expression of Gal-3 and BIM is regulated by the Mst1(Hippo) signalling pathway. The effector of the Hippo pathway is the transcription co-regulator YAP and its paralog TAZ (transcriptional coactivator with PDZ-binding motif) controlling signalling in the Mst1-TG heart leads to down-and up-regulated YAP target genes. For panels a and b, red points denote statistical significance (FDR < 0.05). (c) GSEA enrichment plot shows quantitatively that YAP target genes are collectively up-regulated in the Mst1-TG heart (P < .0005). (d) List of top down-and up-regulated YAP-target genes in Mst1-TG hearts relative to nTG values. For panels a-d, n = 6 for nTG group and n = 7 for TG group. (e) H9c2 cells were transfected with YAP-siRNA or control-siRNA (1 μM for 72 hr). Representative immunoblotting images and changes in protein expression levels of YAP, BIM, and Gal-3. *P < .05, significantly different from CTL (n = 6 per group). Data shown are means ± SEM and were compared by two-tailed Student's t test expression of a number of target genes responsible for cell proliferation and survival (F. X. Yu et al., 2015) . Activation of the Hippo signalling pathway leads to YAP/TAZ phosphorylation and inactivation (F. X. Yu et al., 2015) . In the present study, we consistently observed YAP Ser 127 -hyper-phosphorylation in models with enhanced β-adrenoceptor activity (i.e., isoprenaline treatment and β 2 -TG) or with Collectively, these data suggest involvement of the AC/cAMP/PKA pathway in β-adrenoceptor-Mst1(Hippo) signalling that regulates expression of Gal-3 and BIM. It is well recognized that chronic β-adrenoceptor stimulation occurs in models of heart disease due to , and effect of Gal-3 gene deletion (i.e., TG/KO; n = 5 per group). *P < .05, significantly different from age-matched nTG, # P < .05, significantly different from TG. Data shown are means ± SEM and were compared by two-tailed Student's t test (a), two-way (b) or one-way (c) ANOVA, followed by Bonferroni post hoc test almost any aetiology leading to cardiac apoptosis and fibrosis (G. J. Lee, Yan, Vatner, & Vatner, 2015; Peter et al., 2007; Xiao et al., 2018; Xu et al., 2011) . Our study provides the mechanistic link by showing the coupling of β-adrenoceptors with the Hippo pathway as well as up-regulated Gal-3 and BIM as the target genes. Currently, the potential transcription factors that orchestrate with YAP in mediating up-regulation of Gal-3 and BIM remain undefined. Numerous transcription factors have been implicated in interacting with YAP to regulate target genes (Ikeda & Sadoshima, 2016; J. Wang, Liu, Heallen, & Martin, 2018) , and we previously showed in the heart that isoprenaline-induced up-regulation of BIM requires binding of cMyc and CREB-binding protein to BIM promoter region (Y. Y. Lee et al., 2013) .
In the present study, we addressed the Mst1-dependency of cardiac β-adrenoceptor-mediated activation of the Hippo pathway by investigating dnMst1-TG model (Yamamoto et al., 2003) . Relative to the nTG littermates, isoprenaline-induced YAP hyper-phosphorylation together with up-regulation of Gal-3 and BIM were significantly suppressed in dnMst1-TG hearts, while isoprenaline-induced Gal-3 expression was exaggerated in Mst1-TG hearts. Consistent with this finding is the study by Lee et al. showing that Mst1 inhibition in β 1 -adrenoceptor TG mice by crossing with dnMst1-TG mice rescued cardiomyopathy with suppressed myocardial inflammatory, fibrosis, premature death, and LV dysfunction (G. J. Lee et al., 2015) .
Cardiomyocytes from Mst1-KO mice also show increased resistance to isoprenaline-induced cardiomyocyte apoptosis (G. J. Lee et al., 2015) . The present study and previous studies by Vatner's team (G. J. Lee et al., 2015; Peter et al., 2007) Our finding of YAP hyper-phosphorylation in the Mst1-TG heart implies that increased abundance and activity of Mst1 drives a sustained activation of the Hippo signalling pathway with inactivation of transcriptional activity of YAP. Cardiac-restricted overexpression of Mst1 leads to cardiomyocyte apoptosis and myocardial fibrosis (Yamamoto et al., 2003) . Our recent data from RNA sequencing of Mst1-TG hearts revealed up-regulation of the Hippo pathway-related genes, including Lats, YAP, and Mob1 . The extent of Gal-3 up-regulation is the highest in the Mst1-TG heart, relative to all reported preclinical heart disease models Takemoto et al., 2016; L. Yu et al., 2013) . We recently showed that Gal-3 gene deletion in the Mst1-TG mice is anti-fibrotic For all data sets, n = 6 per group. *P < .05, significantly different from control of the same genotype, # P < .05, significantly different from WT + isoprenaline . Data shown are means ± SEM and were compared by two-way ANOVA, followed by Bonferroni post hoc test. Col, procollagen; αSMA, α-smooth muscle actin; NOX, NADPH oxidase together with alleviation of cardiac dilatation and dysfunction, adding mechanistic insight into fibrogenesis in this model of dilated cardiomyopathy .
Increased p-YAP in our models indicates YAP inactivation.
Unexpectedly, abundance of nYAP, another marker of YAP activity, was increased albeit nYAP/cYAP ratio is lower in isoprenaline treated hearts. Importantly, the three models studied all had increased abundance of total YAP, which is distinct from many other studies showing that activated Hippo signalling increases ratio of p-YAP/total YAP or nYAP/cYAP without change in total YAP (Del Re et al., 2013; Kimura et al., 2016; Plouffe et al., 2016; L. Wang et al., 2016; F. X. Yu et al., 2012) . In addition to YAP, Mst1 expression is also up-regulated by isoprenaline treatment or in β 2 -TG hearts, and we recently observed up-regulated gene expression of the components of Hippo signalling by RNA sequencing in Mst1-TG model . However, Mst1-TG heart also showed concomitant gene up-regulation of factors opposing the Hippo signalling . Of them, Amot and Amotl1 act as YAP/TAZ inhibitors (Chan et al., 2011) and YWHAB and YWHAE code for 14-3-3 involved in YAP cytoplasmic retention (Habbig et al., 2011) . Thus, in the diseased heart in vivo, we reveal a unique and complex situation where sustained β-adrenoceptor stimulation increases protein abundance of many Hippo signalling molecules. Further study is required to explore the mechanism(s) responsible for the up-regulation of Hippo components including YAP and the ultimate effect on YAP transcriptional activity in the setting of sustained activation of β-adrenoceptor-(Mst1)Hippo signalling.
Our study is the first to demonstrate that Gal-3 and BIM, two genes known to contribute to heart disease, are under regulation by the Hippo-YAP signalling, finding that would improve our understanding on the role of the Hippo pathway in heart disease. Based on our findings of up-regulation of Gal-3 and BIM due to enhanced cardiac β-adrenoceptor-Mst1(Hippo) signalling, a maintained YAP activity would be cardioprotective. This view is indeed supported by relatively recent clinical and preclinical studies. In myocardial biopsy of human patients with cardiomyopathy, YAP hyper-phosphorylation is evident indicating activation of the Hippo signalling pathway (Chen et al., 2014; Leach et al., 2017) . Conditional deletion of YAP in embryonic mouse hearts results in myocardial hypoplasia and embryonic lethality (Xin et al., 2013) , while cardiomyocyte-specific deletion of YAP leads to cardiomyocyte apoptosis, dilated cardiomyopathy, and lethality (Del Re et al., 2013; Xin et al., 2013) . Under conditions of chronic myocardial infarction, inactivation of the Hippo pathway by means of deleting Salvador (Leach et al., 2017) or Lats (Heallen et al., 2013) , expressing either mutant dnMst1 gene (Odashima et al., 2007) or mutant dominant-active YAP gene (Lin et al., 2014) , has been shown to lead to better preservation of cardiac function due to improved myocardial regeneration and reduced fibrosis. These findings imply that YAP is critical for basal heart homeostasis, and YAP deficiency exacerbates myocardial apoptosis and fibrosis. . We selected CTGF, Birc5, and Ankrd1 as YAP-target genes (Chen et al., 2014; Kimura et al., 2016; Matsuda et al., 2016; Plouffe et al., 2016) and determined their expression. In hearts of isoprenaline-treated mice or Mst1-TG mice, however, expression of these genes were upregulated, a finding that appears to indicate YAP activation. Considering our finding of up-regulated expression of Gal-3, the molecule possessing transcription activity in the heart (Rabinovich & Toscano, 2009; Suthahar et al., 2018) , we elected to address a possibility that
Gal-3 could regulate expression of these genes. We showed that
Gal-3 gene deletion in both settings (i.e., isoprenaline treatment and Mst1-TG) significantly inhibited expression of these genes. This finding indicates that in the diseased heart, expression of some YAP-target genes might be indirectly regulated by Gal-3, while expression of Gal-3 per se is under tight control by the Hippo signalling. Thus, our results not only add Gal-3 and BIM to the list of YAP-target genes but also demonstrate regulation by Gal-3 of certain YAP-target genes.
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